NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced a milestone of over 1,000 research publications utilizing Flatiron’s electronic health record-derived RWD. This achievement reinforces Flatiron's position as a pioneer in the application of RWD and was made possible through its history of collaboration to support rigorous research projects across the oncology ecosystem, including the 20+ top global developers of oncology therapeutics, academic institutions, policy groups, and regulators around the world..

纽约--（商业新闻短讯）--Flatiron Health是一家领先的healthtech公司，致力于改善癌症护理和利用真实世界数据（RWD）推进研究，今天宣布了1000多篇利用Flatiron电子健康记录衍生RWD的研究出版物的里程碑。这一成就巩固了Flatiron作为RWD应用先驱的地位，并通过其合作历史支持了整个肿瘤学生态系统的严格研究项目，包括全球20多家顶级肿瘤学治疗开发商、学术机构、政策团体和全球监管机构。。

Founded in 2012, Flatiron’s high-quality RWD and real-world evidence (RWE) have transformed data captured during routine care into actionable evidence, improving patient outcomes, supporting FDA regulatory approvals, delivering clinical insights, informing policy, and advancing the company’s mission to improve and extend lives by learning from the experience of every person with cancer.

Flatiron的高质量RWD和真实世界证据（RWE）成立于2012年，已将常规护理期间捕获的数据转化为可行的证据，改善患者预后，支持FDA监管批准，提供临床见解，告知政策，并通过学习每个癌症患者的经验来推进公司改善和延长生命的使命。

Flatiron’s RWD has played a role in generating high-impact evidence, providing expanded therapy options for men with breast cancer, more convenient dosing regimens for people with certain EGFR mutations—meaning less time in treatment, and defined timelines for progression-free lung cancer patients to discontinue immunotherapy treatments after two years..

。。

Flatiron’s publications have contributed to landmark research for people with cancer, representing all of the National Cancer Institute's most common cancer types and many more rare diseases, improving the understanding of solid tumors and hematologic malignancies globally. Research led and authored by Flatiron, as well as studies conducted by collaborators using Flatiron’s RWD, have been published in 142 unique peer-reviewed journals including The Journal of the American Medical Association and presented at prestigious oncology conferences worldwide, including over 350 presentations at the scientific meetings of the American Society of Clinical Oncology (ASCO), and additional high-impact research at the American Society of Hematology (ASH), European Society for Medical Oncology (ESMO), and The Professional Society for Health Economics and Outcomes Research (ISPOR), to name a few..

Flatiron的出版物为癌症患者的里程碑式研究做出了贡献，代表了美国国家癌症研究所所有最常见的癌症类型和更多罕见疾病，提高了全球对实体瘤和血液系统恶性肿瘤的理解。由Flatiron领导和撰写的研究以及合作者使用Flatiron的RWD进行的研究已在142种独特的同行评审期刊上发表，包括《美国医学会杂志》，并在全球著名的肿瘤学会议上发表，包括在美国临床肿瘤学会（ASCO）科学会议上发表的350多篇演讲，以及在美国血液学会（ASH）、欧洲医学肿瘤学会（ESMO）和健康经济与结果研究专业学会（ISPOR）进行的其他高影响力研究。。

Flatiron-led research has been cited over 4,000 times across peer reviewed publications, driving forward the industry’s understanding of RWD and its potential for high-quality evidence generation. Flatiron has also lent expertise across more than 20 manuscripts in collaboration with leading international regulatory bodies and policy organizations, including FDA and NICE..

Flatiron领导的研究在同行评审的出版物中被引用了4000多次，推动了业界对RWD的理解及其产生高质量证据的潜力。Flatiron还与领先的国际监管机构和政策组织（包括FDA和NICE）合作，为20多份手稿提供了专业知识。。

“Reaching this milestone of 1,000 publications underscores the value and quality of our real-world data and expertise, unlocking the power of evidence-based medicine, so every person’s experience can inform and improve outcomes for future patients,” said Jonathan Kish, VP, Head of Research Sciences at Flatiron Health.

Flatiron Health副总裁乔纳森·基什（JonathanKish）表示：“达到1000篇出版物的里程碑，突显了我们现实世界数据和专业知识的价值和质量，释放了循证医学的力量，因此每个人的经验都可以为未来的患者提供信息并改善预后。”。

“Flatiron’s in-house services and experts provide partners across the healthcare ecosystem with high-quality data, as well as study design, analytics, and reporting support for the critical retrospective and prospective research making an impact on our understanding of cancer care.”.

“Flatiron的内部服务和专家为整个医疗保健生态系统的合作伙伴提供高质量的数据，以及对关键回顾性和前瞻性研究的研究设计，分析和报告支持，从而影响我们对癌症护理的理解。”。

Beyond the volume of Flatiron’s published research, the company has pioneered novel RWD methods—such as AI for the extraction of biomarkers and real-world endpoints like tumor response from unstructured data—and RWE approaches for observational research, including comparative effectiveness, external control arms, and assessment of social determinants of health and their related cancer inequities..

除了Flatiron发表的大量研究之外，该公司还开创了新的RWD方法，例如AI，用于从非结构化数据中提取生物标志物和现实世界终点，如肿瘤反应，以及RWE观察性研究方法，包括比较有效性，外部控制手段，以及评估健康的社会决定因素及其相关的癌症不平等。。

Flatiron continues to drive innovation in cancer research. Most recently, the company’s launch of AI-powered Panoramic datasets, including breast and lung cancer, unlocks over 4M de-identified patient records and 1.5B data points in Flatiron’s network for use in research across the patient journey, including commercial tracking and analysis for target populations, emerging and standard of care biomarker data, and safety and outcomes analysis.

。最近，该公司推出了人工智能支持的全景数据集，包括乳腺癌和肺癌，在Flatiron的网络中解锁了超过400万个未识别的患者记录和15亿个数据点，用于整个患者旅程的研究，包括目标人群的商业跟踪和分析，新兴和标准护理生物标志物数据，以及安全性和结果分析。

These solutions are enabling the next generation of cancer research, providing large scale datasets to power studies not previously possible that answer critical questions across the healthcare ecosystem..

这些解决方案正在推动下一代癌症研究，提供大规模数据集来推动以前不可能回答整个医疗保健生态系统关键问题的研究。。

About Flatiron Health

关于扁钢健康

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem.

Flatiron Health是一家healthtech公司，它扩大了肿瘤学护理点解决方案的可能性，并利用数据为每个癌症患者提供更智能的护理。通过机器学习和人工智能，现实世界的证据以及临床试验的突破，我们继续将患者的现实生活经验转化为知识，并创建一个更现代，相互关联的肿瘤学生态系统。

Flatiron Health is an independent affiliate of the Roche Group..

Flatiron Health是罗氏集团的独立附属公司。。